| Drug Type AAV based gene therapy | 
| Synonyms Recombinant serotype 9 adeno-associated virus (AAV) encoding a human galactosylceramidase (GALC) transgene (hGALC)  (Elpida Therapeutics) | 
| Target | 
| Action modulators | 
| Mechanism GALC modulators(galactosylceramidase modulators) | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePreclinical | 
| First Approval Date- | 
| RegulationOrphan Drug (United States) | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Leukodystrophy, Globoid Cell | Preclinical | United States  | 29 Oct 2024 | 





